source
- BMS reports Phase 3 success for RYZ101 in GEP-NET trialBristol Myers Squibb said its radiopharmaceutical candidate RYZ101 met the primary endpoint in a late‑stage Phase 3 study. The drug was acquired in BMS's $4.1 billion purchase of RayzeBio, complete…
- Strategic CDMO partnerships shift from transactional to collaborative, emphasizing risk sharing and regulatory expertiseCDMO-sponsor relationships are moving away from simple outsourcing toward deeper strategic collaboration. Companies now look for partners who share risk, understand regulatory requirements, and pro…